Chelation therapy for heart disease- study runs into serious “side effects”

A study conducted by the NCCAM (National Center for Complementary and Alternative Medicine)- on Edetate Disodium, an amino acid compound used for chelation therapy for heart disease has run into “serious side effects” according to Trine Tsouderos of the Chicago Tribune:

Chelation therapy for heart disease- study runs into serious “side effects”

chelation therapy for heart disease

chelation therapy for heart disease is not easily accepted by orthodox practitioners- but still, "there is no published reports in the scientific literature to disprove the effectiveness of EDTA therapy"

January 23, 201: With study runs into serious “side effect$30 million of taxpayer money, researchers set out to conduct one of the largest studies ever of an alternative medical treatment. The question: Does intravenous chelation therapy to expel metals from the body improve symptoms of coronary artery disease?

The Trial to Assess Chelation Therapy was designed to test a remedy that has been used by tens of thousands of Americans. TACT had the support of a powerful congressman and funding from two branches of the National Institutes of Health. One of them, the National Center for Complementary and Alternative Medicine, was leading the project.

But the trial was marred by problems from the start.

The scientific foundation for chelation was weak, based on decades-old ideas about plaque in the arteries that have never been proved. The treatment was so out of step with mainstream medicine that it was difficult to recruit patients willing to take part. Researchers made confusing statements about the drug being tested, giving volunteers the false impression that it was safer than it was. Several doctors involved in the trial ran into disciplinary problems, and two were convicted of crimes.

Perhaps most troubling: The drug, edetate disodium, turned out to be so risky that theU.S. Food and Drug Administration withdrew its approval. Yet the study was not halted, and the volunteers were not immediately told.

The NIH “is the nation’s premier medical research facility,” says Liz Woeckner, president of Circare, a Philadelphia-based nonprofit that advocates on behalf of people enrolled in clinical trials. “For them to conduct a trial that is unethical and unscientific — and to continue to conduct it? It is just mind-boggling.”

Dr. Josephine Briggs, head of NCCAM since 2008, declined to discuss the study in detail because it is now overseen by the National Heart, Lung and Blood Institute, which is also part of the NIH. But Briggs says that such research is difficult to conduct because “physicians are highly polarized in what they believe.”

Dr. Susan Shurin, acting director of the NHLBI, said in a written statement that a well-designed, sufficiently large clinical trial of chelation therapy was needed. “The lack of compelling evidence to support a widely practiced therapy is an argument FOR doing a randomized trial, not against it,” she wrote. read more

The article goes on to bash other shortcomings of the study including violations from some of the participating doctors,  as “13 of them have run afoul of state medical boards or health departments for actions unrelated to the chelation study. Two physicians had their medical licenses revoked. Two others paid fines for placing misleading ads about the benefits of chelation therapy.”

It’s interesting to note here that what troubles Trine Tsouderos the most is the FDA withdrawal of edetate disodium which is listed by the FDA, WebMD on other orthodox medicine sites as a “drug” medication hence, making it the FDA’s jurisdiction. Other experts not in league with this group refer to edetate disodium and other forms of ETDA as an amino acid compound.

The FDA withdrew the approval of edetate disodium during the study but that is not a surprise- perhaps because according to the FDA, “There have been cases where children and adults have died when they were mistakenly given edetate disodium instead of edetate calcium disodium (Calcium Disodium Versenate) or when edetate disodium was used for “chelation therapies” and other uses that are not approved by the FDA.” The FDA fails to report how many people died but seem to protect companies like Pfizer when deaths pile up. read more

Ray Sahelian reported that 5 people died from Endrate (brand name for edetate disodium. (BTW,  4 children and 1 adult, not adults reported by the FDA)… The deaths however, would seem more likely a misdiagnoses.

Obvious to us that a war is going on here , the lines are drawn and the army with the most money is winning. Sure looks like some people were sore about grants from the government going to someone else this time. But before you, the AMA, FDA and the surgeons dismiss the effectiveness of edetate disodium and EDTA, check out this abstract authored by Elmer M. Cranton, MD & James P. Frackelton, MD:

Benefits of intravenous chelation therapy continue to be unknown to most physicians. A series of unfortunate circumstances led to the cessation of clinical research and delayed wide acceptance of this effective non-invasive therapy, which is much less expensive and infinitely safer than bypass surgery. This article addresses those circumstances and supports the use of EDTA chelation therapy in treating occlusive arterial disease and prefaces summaries posted on this website of a series of highly significant controlled clinical studies proving the safety and effectiveness of this therapy. read more

The future of chelation therapy for heart disease now lies in the hands of the naysayers who when empowered, will make it so us Americans will have to travel overseas for chelation and other advanced treatments for other illnesses.

Related Posts Plugin for WordPress, Blogger... by by by
Share

Stay Informed!

Sign up to receive our newsletter in your mailbox every Thursday!

Speak Your Mind

*